NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

NXL

Nexalin Technology Inc

Jul 03 • 04:00PM ET

0.9601

Dollar change -0.0199
Percentage change -2.03	%

Healthcare • Medical Devices • USA • NASD

Peers: TDOC MNMD CYBN NVCR HRTX TVRD RLMD AXNX NERV KALA

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.76	Insider Own	19.07%	Shs Outstand	17.42M	Perf Week	-3.99%
Market Cap	16.72M	Forward P/E	-	EPS next Y	-0.53	Insider Trans	0.38%	Shs Float	14.10M	Perf Month	-23.80%
Enterprise Value	14.67M	PEG	-	EPS next Q	-0.14	Inst Own	2.28%	Short Float	1.12%	Perf Quarter	-52.23%
Income	-8.55M	P/S	128.62	EPS this Y	28.92%	Inst Trans	5.39%	Short Ratio	1.56	Perf Half Y	-65.95%
Sales	0.13M	P/B	5.50	EPS next Y	10.17%	ROA	-298.36%	Short Interest	0.16M	Perf YTD	-65.21%
Book/sh	0.17	P/C	8.16	EPS next 5Y	-	ROE	-367.74%	52W High	4.49 -78.62%	Perf Year	-42.16%
Cash/sh	0.12	P/FCF	-	EPS past 3/5Y	0.38% -3.66%	ROIC	-367.87%	52W Low	0.59 62.45%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	5.41% -4.04%	Gross Margin	-1082.64%	Volatility	8.59% 7.93%	Perf 5Y	-
Dividend TTM	-	EV/Sales	112.85	EPS Y/Y TTM	-13.73%	Oper. Margin	-6631.95%	ATR (14)	0.09	Perf 10Y	-
Dividend Ex-Date	Mar 23, 2007	Quick Ratio	4.25	Sales Y/Y TTM	-17.50%	Profit Margin	-6526.81%	RSI (14)	31.63	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.56	EPS Q/Q	-6.71%	SMA20	-12.81%	Beta	3.78	Target Price	5.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-47.87%	SMA50	-24.56%	Rel Volume	0.33	Prev Close	0.98
Employees	6	LT Debt/Eq	0.00	Earnings	May 28	SMA200	-56.31%	Avg Volume	101.41K	Price	0.96
IPO	Sep 16, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% 0.00%	Trades		Volume	33,839	Change	-2.03%

May-28-25 10:00AM	Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3 (GlobeNewswire)
May-13-25 08:30AM	Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data (GlobeNewswire)
May-06-25 02:40PM	Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering (GlobeNewswire) -5.26%
May-05-25 08:20AM	Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock (GlobeNewswire) -25.70%
May-01-25 10:30AM	Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback (GlobeNewswire)
09:00AM	Loading…
Apr-24-25 09:00AM	Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia (GlobeNewswire) +5.71%
Apr-23-25 09:15AM	Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO Clinical Research and Patient Management (GlobeNewswire)
Apr-21-25 08:00AM	Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices (GlobeNewswire)
Apr-14-25 12:30PM	Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS) Technology in Treating Substance Use Disorders (GlobeNewswire)
Apr-02-25 08:30AM	Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial (GlobeNewswire) +5.79%
Mar-26-25 08:30AM	Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3 (GlobeNewswire)
Mar-14-25 09:00AM	Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESS Newswire) +10.26%
Mar-03-25 08:30AM	Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS ) Technology for Opioid and Other Substance Use Disorders (GlobeNewswire) -10.70%
Feb-28-25 08:30AM	Nexalin Technology Announces Initiation of Patient Recruitment for UCSD's TBI & PTSD Clinical Study Following IRB Approval (GlobeNewswire)
Feb-26-25 08:30AM	Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board (GlobeNewswire) +7.60%
08:30AM	Loading…
Feb-18-25 08:30AM	Nexalin Technology Announces UCSD IRB Approval for use of HALO Clarity in Clinical Trials for mTBI and PTSD Treatment (GlobeNewswire)
Feb-10-25 09:00AM	Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition (GlobeNewswire) -5.38%
Feb-03-25 08:30AM	Nexalin's Breakthrough DIFS Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study (GlobeNewswire)
Jan-23-25 11:00AM	Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session, Today, January 23 (GlobeNewswire)
Jan-14-25 08:30AM	Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025 (GlobeNewswire) +10.76%
Dec-23-24 10:00AM	Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic (GlobeNewswire)
Nov-26-24 10:00AM	New Peer-Reviewed Publication Validates Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market (GlobeNewswire)
Nov-11-24 08:00AM	Nexalin Technology CEO Provides Letter to Shareholders (GlobeNewswire) -12.11%
Nov-01-24 02:00PM	Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on November 5th (GlobeNewswire) +26.91%
10:34AM	Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements (GlobeNewswire)
09:00AM	LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Oct-28-24 08:30AM	Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease (GlobeNewswire)
Oct-25-24 09:00AM	Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) +6.51%
Oct-22-24 02:15PM	Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA (GlobeNewswire) +20.95%
Oct-17-24 08:30AM	New Study Shows Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer's Patients (GlobeNewswire) +25.71%
08:30AM	Loading…
Oct-14-24 08:30AM	Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs (GlobeNewswire) +15.24%
Sep-05-24 09:00AM	Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment (GlobeNewswire) -10.32%
Jul-26-24 09:55AM	Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) +5.98%
Jul-18-24 08:30AM	Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery (GlobeNewswire) -7.41%
Jul-01-24 02:45PM	Nexalin Technology Announces Closing of $5.2 Million Public Offering (GlobeNewswire)
06:31AM	The 3 Smartest Penny Stocks to Buy With Your Money Right Now (InvestorPlace)
Jun-28-24 08:31AM	Why Is Nexalin Technology (NXL) Stock Down 35% Today? (InvestorPlace) -42.91%
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jun-27-24 09:15PM	Nexalin Technology Announces Pricing of $5.2 Million Public Offering (GlobeNewswire) +8.42%
Jun-26-24 09:00AM	Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal (GlobeNewswire) +20.80%
Jun-20-24 08:30AM	Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer's and Dementia (GlobeNewswire) +5.77%
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
Jun-14-24 09:00AM	Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) -34.85%
08:21AM	Why Is Nexalin Technology (NXL) Stock Down 29% Today? (InvestorPlace)
07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jun-13-24 03:00PM	Nexalin Technology Announces Regulatory Approval to Sell Nexalin's Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa) (GlobeNewswire) +125.10%
Jun-06-24 07:00AM	MicroCap Rodeo's Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies (ACCESSWIRE) +8.67%
Jun-04-24 08:30AM	Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th (GlobeNewswire)
Jun-03-24 08:30AM	FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity Headset Device (GlobeNewswire)
May-30-24 07:47AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) +7.37%
May-22-24 08:30AM	Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts (GlobeNewswire)
May-13-24 10:54AM	NXL Stock Earnings: Nexalin Technology Reported Results for Q1 2024 (InvestorPlace)
May-09-24 08:30AM	Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on May 23 (GlobeNewswire)
Apr-25-24 10:44AM	Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements (GlobeNewswire)
Apr-10-24 08:30AM	Nexalin Technology CEO Provides Letter to Shareholders (GlobeNewswire)
Apr-09-24 08:30AM	Nexalin Technology Accelerates Manufacturing of its HALO Clarity Following Successful Usability, Feasibility, and Electrical Testing (GlobeNewswire)
Apr-04-24 01:00PM	Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity , a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device (GlobeNewswire) -10.42%
11:05AM	Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device (News Direct)
Apr-02-24 08:30AM	Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board (GlobeNewswire) +51.05%
Mar-28-24 08:30AM	Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego (GlobeNewswire) +79.49%
Mar-14-24 08:30AM	Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin's Technology (GlobeNewswire) +20.00%
Mar-13-24 08:30AM	Nexalin Technology Announces Poster Presentation at State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment (GlobeNewswire) +8.17%
Mar-06-24 08:30AM	Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia (GlobeNewswire) +49.55%
Feb-08-24 08:30AM	Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device (GlobeNewswire)
Jan-23-24 08:30AM	Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System (GlobeNewswire)
Jan-11-24 08:30AM	Nexalin Technology Unveils Next-Generation HALO Clarity (GlobeNewswire) +9.67%
Dec-18-23 08:30AM	Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression (GlobeNewswire)
Oct-25-23 08:30AM	Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter (GlobeNewswire) +19.30%
Oct-16-23 08:30AM	Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin's Neurostimulation Device to Penetrate Deep Brain Structures (GlobeNewswire) -28.92%
Aug-07-23 08:30AM	Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms (GlobeNewswire)
Aug-03-23 08:30AM	Nexalins CEO Mark White to be Interviewed Live on The Big Biz Show Today at 3PM Eastern Time (GlobeNewswire)
Jul-26-23 08:30AM	Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies (GlobeNewswire)
Jul-10-23 08:30AM	Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury (GlobeNewswire)
Jun-01-23 08:30AM	Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalins tACS Devices in the Asia Pacific Region (GlobeNewswire) +7.24%
Mar-30-23 06:33AM	Nexalin Technology Full Year 2022 Earnings: US$0.30 loss per share (vs US$1.43 loss in FY 2021) (Simply Wall St.)
Mar-27-23 07:00AM	Nexalin Technology Provides 2022 Year-End Business Update (GlobeNewswire) -18.03%
Jan-24-23 08:30AM	Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory (GlobeNewswire)
Jan-05-23 08:30AM	Nexalin Technology CEO Provides Letter to Shareholders (GlobeNewswire)
Nov-14-22 02:00PM	Nexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety Disorder (GlobeNewswire)
Sep-20-22 01:12PM	Nexalin Technology, Inc. Announces Closing of $9.6 Million Initial Public Offering (GlobeNewswire) -5.33%
Sep-15-22 08:54PM	Nexalin Technology, Inc. Announces Pricing of $9.6 Million Initial Public Offering (GlobeNewswire)
Apr-10-22 06:52PM	What Kind Of Investors Own Most Of Nuix Limited (ASX:NXL)? (Simply Wall St.)

Nexalin Technology, Inc. designs and develops neurostimulation products. Its medical devices help people with mental health illness. The company was founded by John Patrick Claude on October 19, 2010 and is headquartered in Houston, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shelton Carolyn Hamby	Sr. VP - Quality, Regulatory	Mar 12 '25	Buy	2.20	6,000	13,200	30,000	Mar 13 04:52 PM
Owens David	Chief Medical Officer	Feb 04 '25	Buy	3.10	1,000	3,100	155,793	Feb 05 03:17 PM
Owens David	Chief Medical Officer	Feb 04 '25	Buy	2.98	1,000	2,980	154,793	Feb 04 05:05 PM
Owens David	Chief Medical Officer	Jan 28 '25	Buy	2.70	1,500	4,050	153,793	Jan 29 05:22 PM
Owens David	Chief Medical Officer	Jan 13 '25	Buy	2.50	2,000	5,000	151,293	Jan 24 04:55 PM
Owens David	Chief Medical Officer	Jan 23 '25	Buy	2.70	1,000	2,700	152,293	Jan 24 04:55 PM
Owens David	Chief Medical Officer	Oct 28 '24	Buy	2.19	500	1,095	148,293	Oct 30 10:55 AM
Owens David	Chief Medical Officer	Aug 13 '24	Buy	0.95	1,000	950	147,793	Aug 15 04:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NXL

Nexalin Technology Inc

Upgrade your FINVIZ experience